With Moderna Inc.’s U.S. FDA clearance of new mRNA influenza vaccine Mflusiva (mRNA-1010) in the rearview, Wall Street is eagerly anticipating phase III data in the second half of this year from the study called Interpath-001 with intismeran autogene (mRNA-4157 or V940), an mRNA-based individualized neoantigen therapy. Deployed with Keytruda (pembrolizumab), Merck & Co. Inc.'s anti-PD-1 therapy, the drug could end up a blockbuster in melanoma adjuvant therapy, Piper Sandler analyst Edward Tentho